Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus Infections - Pipeline Review, H2 2020, provides an overview of the Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.
MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 14, 8, 3, 76, 32 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 35 and 27 molecules, respectively.
Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus Infections - Pipeline Review, H2 2020, provides an overview of the Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.
MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 14, 8, 3, 76, 32 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 35 and 27 molecules, respectively.
Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Methicillin-Resistant Staphylococcus aureus Infections- Overview
Methicillin-Resistant Staphylococcus aureus Infections- Therapeutics Development
Methicillin-Resistant Staphylococcus aureus Infections- Therapeutics Assessment
Methicillin-Resistant Staphylococcus aureus Infections- Companies Involved in Therapeutics Development
Methicillin-Resistant Staphylococcus aureus Infections- Drug Profiles
Methicillin-Resistant Staphylococcus aureus Infections- Dormant Projects
Methicillin-Resistant Staphylococcus aureus Infections- Discontinued Products
Methicillin-Resistant Staphylococcus aureus Infections- Product Development Milestones
Appendix
Methicillin-Resistant Staphylococcus aureus Infections- Overview
Methicillin-Resistant Staphylococcus aureus Infections- Therapeutics Development
Methicillin-Resistant Staphylococcus aureus Infections- Therapeutics Assessment
Methicillin-Resistant Staphylococcus aureus Infections- Companies Involved in Therapeutics Development
Methicillin-Resistant Staphylococcus aureus Infections- Drug Profiles
Methicillin-Resistant Staphylococcus aureus Infections- Dormant Projects
Methicillin-Resistant Staphylococcus aureus Infections- Discontinued Products
Methicillin-Resistant Staphylococcus aureus Infections- Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by 21st Century Therapeutics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Acticule Life Sciences Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AEON Medix Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AimMax Therapeutics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AlphaMab Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Amicrobe Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Amprologix Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AnyGen Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corp, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aridis Pharmaceuticals Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Arietis Corp, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Armata Pharmaceuticals, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aurigene Discovery Technologies Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Biomendics LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bioseka UAB, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bioversys AG, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Botanix Pharmaceuticals Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cadila Pharmaceuticals Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cantab Anti-infectives Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cellics Therapeutics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Citius Pharmaceuticals Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Combioxin SA, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Crestone Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CSA Biotechnologies LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Curza Global LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DeNovaMed Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Plc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emerald Bioscience Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Enesi Pharma Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ESA Patentverwertungsagentur Sachsen-Anhalt GmbH, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Exbaq LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Galenus Therapeutics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Biotechnologies Pvt Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Global BioLife Inc Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by SciBac Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sentinella Pharmaceuticals Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Shanghai Space Peptides Pharmaceutical Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sinsa Labs Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Soligenix Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Synspira LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TaeJoon Pharmaceuticals Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Telephus Medical LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TGV-Inhalonix Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Theravance Biopharma Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Trellis Bioscience Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Valevia UK Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Venomyx Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Viosera Therapeutics, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Vitas Pharma Research Pvt Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by VLP Biotech Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wockhardt Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by XBiotech Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Yungjin Pharm Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products, H2 2020
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by 21st Century Therapeutics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Acticule Life Sciences Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AEON Medix Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AimMax Therapeutics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AlphaMab Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Amicrobe Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Amprologix Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AnyGen Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corp, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aridis Pharmaceuticals Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Arietis Corp, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Armata Pharmaceuticals, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aurigene Discovery Technologies Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Biomendics LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bioseka UAB, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bioversys AG, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Botanix Pharmaceuticals Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cadila Pharmaceuticals Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cantab Anti-infectives Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cellics Therapeutics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Citius Pharmaceuticals Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Combioxin SA, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Crestone Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CSA Biotechnologies LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Curza Global LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DeNovaMed Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Plc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emerald Bioscience Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Enesi Pharma Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ESA Patentverwertungsagentur Sachsen-Anhalt GmbH, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Exbaq LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Galenus Therapeutics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Biotechnologies Pvt Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Global BioLife Inc Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by SciBac Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sentinella Pharmaceuticals Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Shanghai Space Peptides Pharmaceutical Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sinsa Labs Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Soligenix Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Synspira LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TaeJoon Pharmaceuticals Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Telephus Medical LLC, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TGV-Inhalonix Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Theravance Biopharma Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Trellis Bioscience Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Valevia UK Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Venomyx Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Viosera Therapeutics, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Vitas Pharma Research Pvt Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by VLP Biotech Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wockhardt Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by XBiotech Inc, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Yungjin Pharm Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H2 2020
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
